Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. Maruszczak MJ, Montgomery SM, Griffiths MJS, Bergvall N, Adlard N J Med Econ. 2015 Jun 9:1-24. PMID: 26055952. Abstract CommentRecommendBookmarkWatch